Literature DB >> 21300203

Mirtazapine-induced worsening of restless legs syndrome (RLS) and ropinirole-induced psychosis: challenges in management of depression in RLS.

Amit Chopra1, Dahlia Saad Pendergrass, J Michael Bostwick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21300203     DOI： 10.1016/j.psym.2010.11.009

Source DB:  PubMed          Journal:  Psychosomatics        ISSN： 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  3 in total

1.  Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS).

Authors:  Donald L Bliwise; Rebecca H Zhang; Nancy G Kutner
Journal:  Sleep Med       Date:  2014-06-13       Impact factor: 3.492

2.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

3.  Clinical Study of Restless Leg Syndrome Accompanied by Psychological Symptoms Induced by High-Dose Treatment With Madopar.

Authors:  Lei Zhu; Jing Li; Chongyang Ren; Mei Zhang; Min Xue; Chuanqing Yu; Weili Zhang
Journal:  Front Psychiatry       Date:  2019-05-24       Impact factor: 4.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.